Oncology Institute (TOI) Common Equity (2019 - 2026)

Oncology Institute (TOI) has reported Common Equity for 8 consecutive years, with -$16.3 million the latest figure, recorded in Q1 2026.

• Common Equity for Q1 2026 came in at -$16.3 million, down 421.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.3 million (down 421.27% YoY), and the FY2025 annual result was -$15.7 million, down 538.01% from the prior year.
• Common Equity was -$16.3 million for Q1 2026 at Oncology Institute, down from -$15.7 million in the prior quarter.
• Over five years, Common Equity peaked at $132.0 million in Q1 2022 and troughed at -$16.3 million in Q1 2026.
• Average Common Equity over 5 years is $50.6 million, with a median of $41.3 million recorded in 2024.
• Year-over-year, Common Equity surged 179.98% in 2022 and tumbled 538.01% in 2025.
• Over 5 years, Common Equity stood at $123.2 million in 2022, then tumbled by 53.7% to $57.0 million in 2023, then plunged by 93.71% to $3.6 million in 2024, then sank by 538.01% to -$15.7 million in 2025, then slipped by 3.59% to -$16.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$16.3 million in Q1 2026, -$15.7 million in Q4 2025, and -$12.3 million in Q3 2025.